Long Qing-Hua, Wu Yong-Gui, He Li-Ling, Ding Li, Tan Ai-Hua, Shi He-Yuan, Wang Ping
School of Basic Medicine, Hubei University of Chinese Medicine, Wuhan, 430065, Hubei, China.
School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, 430065, Hubei, China.
Chin Med. 2021 Jan 21;16(1):14. doi: 10.1186/s13020-021-00425-2.
Suan-Zao-Ren Decoction (SZRD) has been widely used to treat neurological illnesses, including dementia, insomnia and depression. However, the mechanisms underlying SZRD's improvement in cognitive function remain unclear. In this study, we examined SZRD's effect on APP/PS1 transgenic mice and mechanisms associated with SZRD's action in alleviating neuroinflammation and improving synaptic plasticity.
The APP/PS1 mice were treated with different dosages of SZRD (12.96 and 25.92 g/kg/day, in L-SZRD and H-SZRD groups, respectively) for 4 weeks. Morris water maze was conducted to determine changes in behaviors of the mice after the treatment. Meanwhile, in the samples of the hippocampus, Nissl staining and Golgi-Cox staining were used to detect synaptic plasticity. ELISA was applied to assess the expression levels of Aβ and Aβ in the hippocampus of mice. Western blot (WB) was employed to test the protein expression level of Aβ, APP, ADAM10, BACE1, PS1, IDE, IBA1, GFAP, PSD95 and SYN, as well as the expressions of JAK2, STAT3 and their phosphorylation patterns to detect the involvement of JAK2/STAT3 pathway. Besides, we examined the serum and hippocampal contents of IL-1β, IL-6 and TNF-α through ELISA.
Compared to the APP/PS1 mice without any treatment, SZRD, especially the L-SZRD, significantly ameliorated cognitive impairment of the APP/PS1 mice with decreases in the loss of neurons and Aβ plaque deposition as well as improvement of synaptic plasticity in the hippocampus (P < 0.05 or 0.01). Also, SZRD, in particular, the L-SZRD markedly inhibited the serum and hippocampal concentrations of IL-6, IL-1β and TNF-α, while reducing the expression of p-JAK2-Tyr1007 and p-STAT3-Tyr705 in the hippocampus of the APP/PS1 mice (P < 0.05 or 0.01).
The SZRD, especially the L-SZRD, may improve the cognitive impairment and ameliorate the neural degeneration in APP/PS1 transgenic mice through inhibiting Aβ accumulation and neuroinflammation via the JAK2/STAT3 pathway.
酸枣仁汤(SZRD)已被广泛用于治疗包括痴呆、失眠和抑郁在内的神经系统疾病。然而,SZRD改善认知功能的潜在机制仍不清楚。在本研究中,我们研究了SZRD对APP/PS1转基因小鼠的影响以及与SZRD减轻神经炎症和改善突触可塑性作用相关的机制。
将APP/PS1小鼠分别用不同剂量的SZRD(L-SZRD组和H-SZRD组分别为12.96和25.92 g/kg/天)治疗4周。进行莫里斯水迷宫实验以确定治疗后小鼠行为的变化。同时,在海马样本中,采用尼氏染色和高尔基-考克斯染色检测突触可塑性。应用酶联免疫吸附测定(ELISA)评估小鼠海马中Aβ和淀粉样前体蛋白(Aβ)的表达水平。采用蛋白质免疫印迹法(WB)检测Aβ、淀粉样前体蛋白(APP)、ɑ-分泌酶(ADAM10)、β-分泌酶(BACE1)、早老素1(PS1)、胰岛素降解酶(IDE)、离子钙接头蛋白1(IBA1)、胶质纤维酸性蛋白(GFAP)、突触后致密蛋白95(PSD95)和突触素(SYN)的蛋白表达水平,以及Janus激酶2(JAK2)、信号转导和转录激活因子3(STAT3)的表达及其磷酸化模式,以检测JAK2/STAT3信号通路的参与情况。此外我们通过ELISA检测了白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)的血清和海马含量。
与未接受任何治疗的APP/PS1小鼠相比,SZRD,尤其是L-SZRD,显著改善了APP/PS1小鼠的认知障碍,神经元损失和Aβ斑块沉积减少,海马中的突触可塑性得到改善(P<0.05或0.01)。此外,SZRD,特别是L-SZRD显著抑制了APP/PS1小鼠血清和海马中IL-6、IL-1β和TNF-α的浓度,同时降低了APP/PS1小鼠海马中磷酸化JAK2-Tyr1007和磷酸化STAT3-Tyr705的表达(P<0.05或0.01)。
SZRD,尤其是L-SZRD,可能通过JAK2/STAT3信号通路抑制Aβ积累和神经炎症,从而改善APP/PS1转基因小鼠的认知障碍并减轻神经退行性变。